Zhejiang Taimei Medical Technology Co., Ltd. (Taimei Tech) reported the on-market repurchase of 43,200 H-shares on 9 June 2026. The shares were bought at prices ranging between HKD 4.30 and HKD 4.44, resulting in a volume-weighted average repurchase price of HKD 4.39838 and an aggregate consideration of HKD 0.19 million.

Post-transaction, Taimei Tech’s issued share capital (excluding treasury shares) decreased by 0.02 % to 200.27 million shares, while total treasury shares increased to 321,000. The overall issued share count remains unchanged at 200.59 million, as the repurchased shares are held in treasury rather than cancelled.

The buyback forms part of the share repurchase mandate granted on 13 June 2025, which permits the company to buy back up to 20.06 million shares. Including the latest transaction, 321,000 shares—equivalent to 0.16 % of the issued share base at the mandate date—have been repurchased under this authority.

In accordance with Hong Kong Stock Exchange rules, Taimei Tech is subject to a moratorium on new share issues or further sales of treasury stock until 9 July 2026. The company confirms that the repurchase complied with Main Board Rule 10.06 and that no material changes have occurred in the previously filed explanatory statement.